Biomed Realty Trust (BMR) Earns Daily News Sentiment Rating of 0.18

News articles about Biomed Realty Trust (NYSE:BMR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biomed Realty Trust earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the real estate investment trust an impact score of 45.9619275960279 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/27/biomed-realty-trust-bmr-earns-daily-news-sentiment-rating-of-0-18.html.

About Biomed Realty Trust

BioMed Realty Trust, Inc operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry.

Insider Buying and Selling by Quarter for Biomed Realty Trust (NYSE:BMR)

Receive News & Ratings for Biomed Realty Trust Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomed Realty Trust Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply